BioCryst (BCRX) Pharmaceuticals announced the appointment of Babar Ghias as CFO and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst price target raised to $15 from $13 at BofA
- BioCryst’s Strategic Sale and Debt Retirement Strengthen Financial Position and Justify Buy Rating
- BioCryst Sells BioCryst Ireland to Neopharmed Gentili
- BioCryst price target raised to $18 from $16 at Wedbush